FDA Warns About Stroke, Artery Tear Risk With Multiple Sclerosis Drug

FDA Warns About Stroke, Artery Tear Risk With Multiple Sclerosis Drug

The FDA is warning that it has received a small number of serious reports of stroke and tears in the lining of head and neck arteries in patients taking the multiple sclerosis (MS) drug Lemtrada (alemtuzumab).

The agency has received reports of 14 such cases since Lemtrada was approved for MS in 2014. Most of the serious effects occurred within one day of receiving the drug. The problems “can lead to permanent disability and even death,” according to the FDA.

As a result, the new risks will be added to Lemtrada’s drug label with the stroke risk added to an existing “black box” warning, the agency’s most serious. Alemtuzumab is also approved under the name Campath as a leukemia treatment, and its label will also get the same changes.

The FDA says that patients should seek emergency treatment immediately if they experience signs or symptoms of artery lining tears or stroke, such as sudden numbness or weakness in the face, arms or legs; sudden confusion or trouble speaking; sudden vision problems; sudden difficulty walking or maintaining balance; and sudden severe head or neck pain.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Researchers have managed to create artificial red blood cells that can transport medication. Compared to the popular anticoagulant Warfarin, NOAC’s may be superior for treating atrial fibrillation patients with prior intracranial hemorrhage. Also, surgery may be the preferred choice for reducing leg pain in patients with sciatica.  Synthetic Red Blood…

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

  • Advertisement